ZEVTERA Drug Patent Gets FDA Extension Green Light
Published Date: 6/16/2025
Notice
Summary
The FDA has officially set the review period for ZEVTERA, a human drug product, so its patent can be extended. This means the company behind ZEVTERA gets more time to protect their invention, helping them keep making and selling the drug. If you’re in the drug business or follow patents, this update shows when and how patent extensions happen.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Patent Extension Determination for ZEVTERA
The FDA has determined the regulatory review period for the human drug ZEVTERA so the patent holder can seek an extension of the patent that claims the drug. This lets the company behind ZEVTERA have more time to protect its invention and continue making and selling the drug. The notice was published because an application for patent extension was submitted to the U.S. Patent and Trademark Office.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in